β-casein CRISPR/Cas9 KO Plasmid (h): sc-402248
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- β-casein CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the β-casein genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: β-casein Antibody (F20.14): sc-53189
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-casein CRISPR/Cas9 KO Plasmid (h) | sc-402248 | 20 µg | $397.00 |
Overview
CSN2 encodes human β-casein, a secreted phosphoprotein that constitutes a major component of milk and contributes to neonatal nutrition by binding calcium and phosphate in casein micelles. Its expression is tightly regulated during mammary epithelial differentiation and lactation, integrating endocrine cues through prolactin receptor–JAK2/STAT5 signaling and cooperating pathways that shape secretory programs. CSN2 transcriptional output is commonly used as a marker of functional lactogenic differentiation and mammary gland developmental state in cell-based models. Dysregulation of milk protein gene programs, including CSN2, is relevant to studies of mammary epithelial plasticity and breast biology, where altered differentiation signatures can accompany disease-associated phenotypes.
β-casein CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CSN2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CSN2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CSN2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish β-casein protein expression.
This CRISPR knockout system enables efficient generation of CSN2-deficient cell models for investigation of β-casein signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CSN2 exon(s) critical for β-casein function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CSN2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by β-casein CRISPR/Cas9 KO Plasmid (h) and β-casein CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CSN2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by β-casein HDR Plasmid (h) and β-casein HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CSN2 homology arms to support homology-directed repair at defined CSN2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.